Target intelligence / Profile preview

Human immunodeficiency virus RNA/genome sequences (HIV RNA)

Target
HIV RNA
Molecular classification
Viral genome, Nucleic acid, Ribonucleic acid, Deoxyribonucleic acid, Other
01

Overview

Human immunodeficiency virus (HIV) RNA and genome sequences represent critical therapeutic targets for curing or achieving long-term functional control of HIV-1 infection. The HIV genome consists of single-stranded RNA in the virion, which is reverse-transcribed into double-stranded proviral DNA and integrated into the host cell genome, establishing a persistent latent reservoir that is unaffected by standard antiretroviral therapy (ART). Novel therapeutic strategies directly target these viral nucleic acid sequences to either excise the integrated provirus or silence viral gene expression. For instance, CRISPR/Cas9-based therapies like EBT-101 utilize guide RNAs to make precise cuts in the integrated HIV genome, aiming to excise replication-competent proviral DNA. Additionally, RNA-based approaches, including short hairpin RNAs (shRNAs like PromA), antisense oligonucleotides (ASOs), and ribozymes, target viral transcripts to induce post-transcriptional gene silencing, transcriptional gene silencing, or RNA degradation. While these approaches offer a potential path toward a functional cure, significant challenges remain, including the risk of off-target editing, incomplete clearance of the latent reservoir leading to viral rebound, and the rapid emergence of viral escape mutants due to the high mutation rate of HIV.

Other names
HIV-1 RNAHIV-1 genomeHIV proviral DNAHIV-1 proviral DNAHuman immunodeficiency virus type 1 genomeHIV-1 genomic RNAHIV-1 pre-mRNAHIV-1 transcripts
02

Mechanism of action

Gene editing (CRISPR/Cas9-mediated excision of proviral DNA), RNA interference (shRNA/siRNA-mediated post-transcriptional gene silencing or transcriptional gene silencing), antisense oligonucleotide-mediated RNase H cleavage or steric hindrance, and decoy RNA-mediated sequestration of viral proteins.

03

Biological functions

Viral replicationViral transcriptionViral translationViral packagingViral latencyOther
04

Disease associations

InfectionOther
05

Safety considerations

Off-target gene editingViral rebound after treatment interruptionImmunogenicity against Cas9 or viral vectors (AAV9, lentivirus)Insertional mutagenesis (for integrating vectors)Incomplete excision of the provirus leading to replication-competent escape mutantsTransient transaminase elevations
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

HIV-1 viral load (plasma HIV RNA)CD4+ T-cell countHIV-1 proviral DNA levelsEBT-101 biodistributionEBT-101 immunogenicityHIV-1 reservoir persistence

Beyond the preview

Go deeper on Human immunodeficiency virus RNA/genome sequences (HIV RNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human immunodeficiency virus RNA/genome sequences (HIV RNA).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call